Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The hepatic fatty acid synthesis pathway is a metabolic process by which hepatocytes (liver cells) convert acetyl-CoA, primarily derived from carbohydrates or amino acids, into long-chain fatty acids. This multi-step process begins in the mitochondria, where acetyl-CoA is exported to the cytosol as citrate, then reconverted and processed through a series of cytosolic reactions catalyzed by enzymes such as acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS)[1][2][3][4][6]. The pathway is tightly regulated by metabolic and hormonal signals (notably insulin and glucose), with key transcriptional regulators including SREBP-1c and ChREBP[1]. Its physiologic roles include the synthesis and storage of energy as triglycerides and the provision of lipid substrates for membrane biosynthesis. Dysregulation contributes to the pathogenesis of metabolic diseases such as non-alcoholic fatty liver disease and obesity[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hepatic fatty acid synthesis pathway.